RecruitingPHASE1, PHASE2NCT06389877

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beam Therapeutics Inc.
Principal Investigator
Medical Information
Beam Therapeutics
Intervention
BEAM-302(drug)
Enrollment
106 enrolled
Eligibility
18-70 years · All sexes
Timeline
20242030

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06389877 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency

← Back to all trials